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ABSTRACT
The phylogenetically-derived secondary structures
of telomerase RNAs (TR) from ciliates, yeasts and
vertebrates are surprisingly conserved and contain
a pseudoknot domain at a similar location down-
stream of the template. As the pseudoknot domains
ofTetrahymenaTR(tTR)andhumanTR(hTR)mediate
certain similar functions, we hypothesized that
they might be functionally interchangeable. We con-
structed a chimeric TR (htTR) by exchanging the hTR
pseudoknot sequences for the tTR pseudoknot
region. The chimeric RNA reconstituted human
telomerase activity when coexpressed with hTERT
in vitro, but exhibited defects in repeat addition
processivity and levels of DNA synthesis compared
to hTR. Activity was dependent on tTR sequences
within the chimeric RNA. htTR interacted with
hTERT in vitro and dimerized predominantly via a
region of its hTR backbone, the J7b/8a loop.
Introduction of htTR in telomerase-negative cells
stably expressing hTERT did not reconstitute an
active enzyme able to elongate telomeres. Thus, our
resultsindicatethatthechimericRNAreconstituteda
weakly active nonprocessive human telomerase
enzyme in vitro that was defective in telomere
elongation in vivo. This suggests that there may be
species-specific requirements for pseudoknot
functions.
INTRODUCTION
In most eukaryotes, the physical chromosome end is consti-
tuted by telomeres, tandem repeats of short G-rich sequences
complexed with proteins (1). Telomerase, the telomere-
speciﬁc DNA polymerase counterbalances the ‘end replication
problem’ by synthesizing telomeric tracts (1,2). The enzyme
possesses two core components, a catalytic reverse tran-
scriptase subunit TERT (telomerase reverse transcriptase)
and an RNA subunit TR (telomerase RNA) that carries the
template for the replenishment of the telomeres (3). The genes
encoding the two core telomerase subunits have been cloned
from various eukaryotic organisms (3). The TERT subunit can
be divided into three regions: the N-terminus, the RT domain
and the C-terminus (4). The N- and C-terminal regions of
TERT, which are not conserved among reverse transcriptases,
mediate telomerase-speciﬁc functions: both are implicated in
telomerase activity, processivity, multimerization, localiza-
tion and telomere maintenance (4). However, binding of
TERT to TR appears restricted to the N-terminus (5–9).
The TR subunit varies considerably in length: 150–200 nt
in ciliates,  1300 nt in yeasts, and 400–600 nt in vertebrates
(10–12). Despite a poor primary sequence conservation
between ciliate telomerase RNAs, phylogenetic comparisons
supported by chemical modiﬁcation and protection analyses
revealed that these RNAs share a common secondary structure
(13–15). Similar analyses have been used to demonstrate that
vertebrate telomerase RNAs also share a common secondary
structure (10,16).
Interestingly, in the ciliate, vertebrate and yeast telomerase
RNAs, a pseudoknot domain occupies a similar position, 30 of
the template (10,17). Mutations expected to disrupt the
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telomerase RNAs impair catalytic activity and compensatory
mutations restore activity, supporting the existence of the
pseudoknot structure (18–22).
In vivo, alteration of Tetrahymena pseudoknot topology
leads to defects in enzyme assembly and activity (19) and
in vitro, the disruption of the pseudoknot sequences alters
the reconstitution of an active enzyme (23,24). Similarly, in
vertebrates and yeasts, both the sequence and topology of the
pseudoknot are critical for telomerase activity. Mutations in
the human telomerase RNA (hTR) P3 pseudoknot helix
(Figure 1B) signiﬁcantly alter the reconstitution of a catalyt-
ically active enzyme in vitro (21,22). Using cells derived from
the telomerase RNA (mTR) knockout mouse, Martin-Rivera
et al. (20) demonstrated that all mutations disrupting the pseu-
doknot sequence and putative P3 helix structure affect in vivo
reconstitution of telomerase activity. Similarly, disrupting the
putative long-range base-pairing of the budding yeast
Kluyveromyces lactis pseudoknot TR affects telomerase
activity (25).
Telomerase, like all nucleic acid polymerases, performs
nucleotide addition (type I) processivity. However, telomerase
possesses a unique feature, repeat addition (type II) processiv-
ity, deﬁned as the reiterative copying of the template to gen-
erate multiple repeats before dissociation from a single DNA
substrate (26). Early experiments in which a hybrid telomerase
enzyme assembled in vivo from Glaucoma chattoni
telomerase RNA and Tetrahymena thermophila telomerase
proteins implicated nontemplate RNA domains in
processivity (27). Speciﬁcally, the pseudoknot has been
implicated in the processivity of both the Tetrahymena and
human enzymes. The pairing potential of the pseudoknot heli-
ces (IIIa/IIIb) as well as the entire helix III are important in
conjunction with helix IV for repeat addition processivity of
Tetrahymena telomerase (Figure 1A) (24). Mutations in the
hTR P3 pseudoknot helix severely affects DNA synthesis
levels and repeat addition processivity (8,22). In addition,
other elements such as the P1 helix as well as nucleotides
30 of the template (Figure 1B) in the pseudoknot/template
region (hTR nucleotides 1–209) also regulate processivity
(8,21). The pseudoknot/template domain (nucleotides 1–
102) of the Tetrahymena telomerase RNA (tTR) contains a
template-adjacent motif, the template recognition element
(28), which may act in concert with helix IV to stimulate
processivity (29). Similarly, in Saccharomyces cerevisiae
the pseudoknot/template domain contains a stem–loop (differ-
ent from the pseudoknot itself) that plays a role in template
sequence usage and template boundary deﬁnition (30).
Accordingly, the P1 helix of the human pseudoknot/template
domain constitutes a determinant for template boundary def-
inition (31).
The hTR P3 pseudoknot helix has also been implicated in
hTR dimerization (32). Dimerization seems to be critical for
human enzyme activity, however Tetrahymena telomerase is
active as a monomer (32,33). Although the pseudoknot and
pseudoknot/template regions are directly involved in binding
of TR to TERT in yeasts and human, respectively (6,8,34,35),
in Tetrahymena, the binding of TR to TERT is not dependent
on the pseudoknot in vitro (23).
The pseudoknot domain is also implicated in telomere
maintenance. Dyskeratosis congenita (DC) is a rare multi-
system syndrome characterized by defects in highly regener-
ative tissues, increased tumour susceptibility, premature
aging, and early death due to bone marrow failure (36,37).
The autosomal dominant form of the disease is characterized
by mutations in hTR, some of which are located in the pseu-
doknot/template domain (36–39). Short telomeres are
observed in autosomal dominant DC suggesting a correlation
between telomere length maintenance and DC phenotypes
(37). Likewise, mutations disrupting the pairing potential of
S.cerevisiae and K.lactis telomerase RNA pseudoknots impair
telomerase action in vivo, causing a marked decrease in
telomere length (25,30).
Thus, not only are the structure and template-adjacent posi-
tion of the pseudoknot domain conserved in the telomerase
RNAs from ciliates, yeasts and vertebrates, but the pseudoknot
domain also mediates similar functions in these organisms.
Thus, we considered that the pseudoknot regions from differ-
ent telomerase RNAs might be functionally equivalent. To test
this hypothesis, we exchanged the hTR pseudoknot for the
Tetrahymena telomerase RNA pseudoknot, creating an
hTR-tTR chimera (called htTR). htTR reconstituted a weakly
active, nonprocessive chimeric human telomerase enzyme
in vitro that was defective in telomere elongation. Functional
impairment could not be attributed to a lack of htTR–hTERT
interactions, in vitro and in vivo, or to defects in dimerization
in vitro.
Figure 1. (A and B) Secondary structures of hTR and tTR [adapted from
(10,13)]. Helices I, II, III, IIIa/IIIb and IV and the template are indicated for
tTR. The template, helices P1, P2a.1, P2a, P2b, P3 (CR2–CR3), P6.1, the
H/ACA box, the CR4–CR5 and J7b/8a regions are indicated for hTR. The
arrows indicate the boundaries of the mutations in the tTR and hTR variants
usedinthisstudy.TheboxeshighlightthehTRandtTRnucleotidesdeletedand
inserted respectively, to construct the htTR chimera.
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Constructs
phTR+1 (40) and pET28b-hTERT WT (41), pCR3.1-Flag-
hTERT WT (5) and pCR3.1-Flag-hTERT 1-250, 300-600
(8) were described previously. The pET28a-tTERT plasmid
was a gift from Dr T.R. Cech (Howard Hughes Medical
Institute, Boulder, CO).
The method to construct phtTR was adapted from Ho
et al. (42). Four sets of primers were designed: the primer
hTR-tTR1 (50-GGGGAAGCTTTAATACGACTCACTAT-
AGGGTTGCGGAGGGTGGGCCTG-30) which contains
nucleotides (nt) 1–18 of hTR. The primer hTR-tTR2 (50-
GAAGGTTATATCAGCACTAGATTTGTTAGGGTTAGA-
CAAAAAATGGCC-30) contains nt 33–56 of hTR plus nt
52–82 of tTR. The primer hTR-tTR3 (50-GGCCATTTTT-
TGTCTAACCCTAACAAATCTAGTGCTGATATAACCT-
TC-30) is the exact complement of the primer hTR-tTR2. The
primer hTR-tTR4 (50-GCTCTAGATTACCACTTATTT-
GAACCTAATTG-30) contains nt 82–102 of hTR plus nt
159–183 of hTR. In the ﬁrst PCR step (step I), 1 ng of the
pGRN33 plasmid [genomic clone of hTR, (43)] was ampliﬁed
by using 1 mM ﬁnal of each hTR-tTR 1 and 2 primer, 1· Pfu
PCR buffer (Stratagene), 0.25 mM dNTPs, 5 ml dimethyl
sulfoxide (Sigma), and 2.5 U of Pfu turbo for 1 min, 94 C,
2 min, 50 C and 3 min, 72 C (30 cycles). In the second PCR
step (step II), the same method as above (step I) was used to
amplify the pCG1 plasmid [genomic clone of tTR (44)] with
the hTR-tTR 3 and 4 primers. In the third PCR step (step III),
equivalent amount (10 ml) of the PCR products from the steps I
and II was mixed in the presence of hTR-tTR 1 and 4 primers,
and the same method as in step I was applied to obtain a PCR
product. The HindIII–XbaI treated PCR product was cloned
into phTR+1 digested with the same enzymes.
phTR 1–56 and phTR 160–451 were generated by PCR
using the phTR+1 plasmid with the primers hTR-tTR1 (see
above) and hTR56 (50-CCCCGGATCCGTTAGGGTTA-
GACA-30), and the primers hTR160 (50-GGGGAAGCTT-
TAATACGACTCACTATAGGGTAGAGCAAACAAAAA-
ATG-30), and hTR451 (50-CCCCGGATCCTGCGCATGT-
GTGAGCCGAGTCCTGGG-30), respectively. BamHI–
HindIII treated PCR products were cloned into pUC119 diges-
ted with the same enzymes.
phTR (phTR P1sub and phTR 395–398) and phtTR (phtTR
stem IIIa, phtTR stem IIIb, phtTR P1sub and phtTR 395–398)
substitution variant constructs were generated by the Quick
Change Site-Directed Mutagenesis method from Stratagene.
The following primers were used: PN 84–87 F (50-
GCTGATATAACCTTCACCAATTACCAACAATAAGTG-
GTAATAGAGC-30) and PN 84–87 R (50-GCTCTATTAC-
CACTTATTTGTTGGTAATTGGTGTTGGTTATATCAG-
C-30) to generate the phtTR stem IIIb plasmid in which
nt 84–87 are replaced by nt 69–72; PN F (50-GT-
GCTGATATAACCTTCTGGTGAATGGTTCAAATAAGT-
GGTAATCTAGAGC-30) and PN R (50-GCTCTAGATTAC-
CACTTATTTGAACCATTCACCAGAAGGTTATATCAG-
CAC-30) to generate the phtTR stem IIIa plasmid in which nt
76–83 are replaced by nt 92–99; hTR190-QCM-F (50-
CAAACAAAAAATGTCAGCTGCTGCTGGGGUGGUGG-
GGCCTCCCGGGGACCTGCGGCGGGT-30) and hTR190-
QCM-R (50-ACCCGCCGCAGGTCCCCGGGAGGCCCCA-
CCACCCCAGCAGCTGACATTTTTTGTTTG-30) to gener-
ate the phTR P1sub and phtTR P1sub plasmids in which hTR
nt 190–199 are replaced by hTR nt 27–36; hTR395-398F (50-
GGAACGGAGCGAGTCCCCGCTTTTGGCGCGATTCCC-
TGAGC-30) and hTR395-398R (50-GCTCAGGGAATCGC-
GCCAAAAGCGGGGACTCGCTCCGTTCC-30) to generate
the phTR 395–398 and phtTR 395–398 plasmids in which nt
395–398 are replaced by TTTT. The underlined sequences in
the primers represent the mutations introduced. The pGEM36
plasmid, encoding hTR C4A2 which dictates the synthesis of
T2G4 sequences, was described previously (40).
The pcDNA3-Hygromycin-hTR and pcDNA3-
Hygromycin-htTR constructs were generated from the
pcDNA3-Hygromycin plasmid (Invitrogen, gift from
Dr A. Koromilas, Lady Davis Institute Montreal, Quebec,
Canada). HindIII–BamHI-digested hTR and htTR from the
phTR+1 and phtTR plasmids, respectively, were cloned into
the pcDNA3-Hygromycin plasmid digested with the same
enzymes. The identities of all the constructs were veriﬁed
by restriction enzyme analysis and/or sequencing.
Cell line, transfection and cellular extract
The VA13-hTERT is a telomerase-negative ALT (alternative
lengthening of telomeres) cell line which has been transfected
with the human telomerase catalytic subunit, hTERT (45)
(kindly provided by Dr S. Bachetti, Regina Elena Cancer
Institute, Rome, Italy). VA13-hTERT cells were grown in
a-MEM with 10% fetal bovine serum (FBS). Stable cell
lines were obtained by transfection with the vector
pcDNA3 alone, pcDNA3-hTR or pcDNA3-htTR. For the cel-
lular extracts, cells were lysed in NP-40 lysis buffer [10 mM
Tris–HCl (pH 7.5), 1mM MgCl2, 1mM EGTA, 10% glycerol,
150 mM NaCl, 0.1 mM phenylmethylsulfonyl ﬂuoride, 5 mM
b-mercaptoethanol and 1% NP-40] and incubated on ice for
10 min. The cell lysates were centrifuged at 13226 g for
20min at 4 C. The supernatant was further used for the experi-
ments. Clonal populations were selected with 105 mg/ml
hygromycin for 3–4 weeks, and were routinely subcultured
at a 1:4 split ratio as they reached conﬂuence.
RNA isolation and RT–PCR
Total RNA was isolated using TRIzol (Invitrogen) according
to the manufacturer’s instruction. Reverse transcription of the
RNAs was followed by PCR to detect hTR WT and htTR
expressions with the following primers: 50-TCTAACCC-
TAACTGAGAAGGGCGTAG-30 and 50-GTTTGCTCTA-
GAATGAACGGTG-30. hTERT expression was revealed
with the primers hT1, 50-AAGTTCCTGCACTGGCTGAT-
GAG-30 and hT2, 50-TCGTAGTTGAGCACGCTGAACAG-
30. Human GADPH was ampliﬁed with primers RT11,
50-CGGATCAACGGATTTGGTCGTAT-30 and RT12,
50-TGCTAAGCAGTTGGTGGTGCAGGA-30 as a control.
In vitro reconstitution of telomerase, TRAP and
direct primer extension assays
TERT proteins were synthesized in rabbit reticulocyte lysate
(RRL) by incubating 25 ng of various TERT constructs per ml
of RRL in the presence of in vitro transcribed telomerase
RNAs (10 ng/ml of RRL) and [
35S]methionine. Direct primer
extension telomerase assay was performed as described
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per reaction. The TRAP (telomeric repeat ampliﬁcation pro-
tocol) assay was performed as described previously using the
ACX primer (7), except for the experiments reported
in Figure 2B, which were performed with the ACT-C4A2
primer (50-GCGCGGCCAACCCCAACCCCAACCCCAA-
CC-30) where indicated.
The ladder of products generated by the RRL-reconstituted
enzymes and the products corresponding to the PCR internal
control (IC) were quantiﬁed using Molecular Dynamics
Figure 2. The chimerareconstituteshumantelomerase activityuponhTERTexpressionin vitro.( A) Upperpanel.The chimerareconstitutestelomerase activityby
TRAP. Telomerase complexes were reconstituted in RRL, and telomerase activity was detected using TRAP. IC indicates the internal PCR control. Lower panel.
InvitrosynthesisofhTERTandtTERT.1mlofthecorrespondingRRLreactionwasanalyzedbySDS–PAGE.(B)Upperpanel.tTRdoesnotfunctionwithhTERTto
reconstitutetelomeraseactivitybyTRAP.TelomerasecomplexeswerereconstitutedinRRL,andtelomeraseactivitywasdetectedbyTRAP,usingamodifiedprimer
complementarytothetemplatesequenceoftTR(ACT-C4A2)(lanes1–9)ortheACXprimer(lanes10and11).Lowerpanel.InvitrosynthesisofhTERTandtTERT.
ThecorrespondingRRLreactionof1mlwasanalyzedbySDS–PAGE.(C)hTR1-56andhTR160-451donotreconstitutetelomeraseactivityasmeasuredbyTRAP.
Thesame reconstitutionmethodasin(A) wasused.(D) Amutationwithinthe tTRpseudoknotsequencesinhtTR significantly reducesthe activityreconstitutedby
the chimeric enzyme. The same method as in (A) has been used. %WT indicates the average percentage of WT telomerase activity derived by quantification of the
variants’telomeraseactivitiesrelativeto theWTtelomeraseactivityandthestandarddeviation.Atotaloffiveexperimentswereperformed.(E) Diagramdepicting
thepredictedalignmentsoftheoligonucleotides(usedinFandH)withthehTRtemplate.Thearrowindicatesthetranslocationoftheprimeralongthetemplateafter
the first round of DNA synthesis by the telomerase enzyme. P stands for primer length. (F) The chimeric enzyme is nonprocessive. RRL-reconstituted human
telomerase catalytic activity was tested using the direct primer extension telomerase assay with the indicated 30 end-labeled biotinylated primers. (P + 4),
(P + 4) + 6, (P + 6), (P + 6) + 6 indicate the position of the products synthesized by telomerase (arrows, asterisks). (G) The chimeric enzyme nonprocessively
elongatesaTetrahymena-liketelomericoligonucleotide,(T2G4)3.Thesamemethodasin(F)wasused.(H)ThehtTRstemIIIa-andstemIIIb-reconstitutedenzymes
are nonprocessive. The same method as in (F) was used.
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described (7). The quantiﬁcation of the nucleotide addition
processivity of the telomerase enzymes was performed as
described previously (7).
In vitro RNA binding assay
RNA binding was performed as described previously (8),
except that 8.82 mgo fa-Flag M2 antibody (Sigma) or
5.4mgofanti-hTERTantibody(6)permlwereusedforimmuno-
precipitations. The FLAG RID2 hTERT protein was immuno-
precipitated with the a-Flag antibody. hTERT was
immunoprecipitated with the anti-hTERT antibody (6). The
quantiﬁcations were performed as described previously (6).
In vitro hTR/htTR dimerization assay
Dimerization assays were performed as described previously
(32). The monomers and dimers formed by each RNA at 37 C
were quantiﬁed using Molecular Dynamics Densitometer and
ImageQuant software. For monomer and dimer signals in
each lane, background (region directly above signals) was
subtracted and the percentage of dimer for one RNA
at 37 C was determined by the following formula: (corrected
dimer value)/(corrected monomers values + corrected dimers
values) · 100.
Q-FISH
Q-FISH assay was performed as described previously (46).
Immunoprecipitation assay, northern and
western blots analyses
A total of 50 mg of extracts from two hTR-transfected, two
htTR-transfected and one vector-transfected clones were
immunoprecipitated with the anti-hTERT antibody (6).
Final volume of 100 ml beads were divided in three aliquots:
10 ml were dedicated to a TRAP assay, 30 ml to the western
blot and 60 ml to the northern blot analyses. 30 ml of beads
were loaded on a SDS–PAGE. Anti-hTERT antibody of
0.3 mg/ml was used to reveal the presence of the hTERT
proteins. The RNAs were extracted from the 60 ml of beads
with phenol/chloroform/isoamyl. The northern blots were
probed with a
32P-labeled hTR cDNA directed against a com-
mon region of hTR and htTR.
RESULTS
Construction of an hTR-tTR pseudoknot chimera
To test the functional equivalence of the human and
Tetrahymena telomerase RNA pseudoknot domains, we
exchanged hTR pseudoknot sequences for tTR pseudoknot
sequences while maintaining the other domains of hTR,
including the P1 helix (Figure 1B). The pseudoknot/template
domain of hTR (nucleotides 1–209) contains several regions:
the P1 helix, the template and the pseudoknot, comprised of
helices P2a.1, P2a, P2b and P3 (10) (Figure 1B). As we were
interested in understanding the effect of a pseudoknot
exchange on human telomerase function, we kept the hTR
template (nucleotides 46–56), necessary to assay human
telomerase activity; hTR nucleotides 170–200 were also main-
tained in the chimera because of their importance for
human telomerase catalytic activity (40,47,48). Thus, hTR
nucleotides 57–159 were deleted, including helices P2a.1,
P2a, P2b and part of P3, and replaced by tTR nucleotides
52–102, including pseudoknot helices IIIa and IIIb
(Figures 1A and B). The resulting chimera, called htTR, com-
prisesnucleotides1–56ofhTR,52–102oftTRand160–451of
hTR.
Expression of the chimera and hTERT in vitro
reconstitutes telomerase activity as
measured by TRAP
To test if the introduction of the tTR pseudoknot in the hTR
backbone would generate an in vitro catalytically functional
enzyme, we ﬁrst analysed the activity of the chimeric enzyme
by TRAP. We reconstituted the chimeric telomerase enzyme
by expressing hTERT in the presence of htTR using an in vitro
transcription and translation RRL system. Since the chimera
contains Tetrahymena pseudoknot sequences, we also tested
whether htTR could reconstitute telomerase activity upon
expression of the Tetrahymena catalytic subunit tTERT.
Telomerase reconstituted with htTR exhibited decreased
activity compared to the enzyme reconstituted with hTR
(Figure 2A, lanes 2 and 4). No reconstitution of telomerase
activity was detected with hTR and htTR upon expression of
tTERT (upper and lower panels of Figure 2A, lanes 3 and 5),
suggesting that tTERT cannot function with hTR, or the tTR
region in htTR, to reconstitute telomerase activity. Thus, the
reconstituted chimeric human enzyme was partially active by
TRAP in vitro.
TodetermineiftTRcouldreconstitute activitywith hTERT,
we analyzed telomerase activity by TRAP using a modiﬁed
primer complementary to the tTR template sequence (ACT-
C4A2) (Figure 2B). An hTR mutant, hTR C4A2, reprogrammed
to direct the synthesis of T2G4 repeats by human telomerase
was used as a positive control (40,43). Enzymes reconstituted
with hTERT and hTR or htTR (upper and lower panels of
Figure 2B, lanes 1 and 3), but not with tTR (Figure 2B,
lane 5) generated elongation products. However, as previously
shown with the ACX primer (Figure 2A), no telomerase activ-
ity was detected with enzymes reconstituted with tTERT and
hTRor htTR (upper and lower panels of Figure 2B, lanes 2and
4). Some elongation products were detected for enzymes
reconstituted with tTERT and tTR (upper and lower panels
of Figure 2B, lane 6), and with hTERT and hTR C4A2 (upper
and lower panels of Figure 2B, lane 7). Similar TRAP elonga-
tion products generated by telomerase reconstituted with
hTR C4A2 have been reported previously (40,43).
hTR1-56 and hTR160-451 do not reconstitute
telomerase activity in vitro as measured by
TRAP upon hTERT expression
A functional humantelomerase canbe reconstituted invitro by
expressing hTERT, and combining in trans two independently
inactive hTR fragments, the pseudoknot/template and the
CR4–CR5 domains (47–49). Thus, we asked if the hTR
sequences remaining in the chimera could be sufﬁcient to
mediate its activity. We constructed the hTR variants 1–56
and 160–451, which correspond to the hTR regions present
in the chimera, and tested their capacity to generate telomerase
activity in trans upon hTERT expression. The hTR fragments
1–209 and 207–451 were used as a positive control, since in
5450 Nucleic Acids Research, 2005, Vol. 33, No. 17concert with hTERT they reconstitute partial telomerase activ-
ity in vitro (49).
The hTR fragments 1–209 and 207–451 did not independ-
ently reconstitute telomerase activity (Figure 2C, lanes 5 and
6), but reconstituted partial telomerase activity when added
in trans (Figure 2C, lane 9) (49). On the contrary, hTR 1–56
and hTR 160–451 did not independently reconstitute telomer-
ase activity in the presence of hTERT (Figure 2C, lanes 3 and
4) or when mixed in trans with hTERT (Figure 2C, lane 7).
This result suggests that hTR nucleotides 1–56 and 160–451
may not be sufﬁcient to reconstitute telomerase activity in the
context of the chimera, and that tTR sequences 52–102 may
play a role in the function of the chimeric RNA.
Mutation of tTR pseudoknot sequences in htTR
impairs reconstitution of telomerase
activity as measured by TRAP
Disrupting the putative base-pairing of the pseudoknot
structure in ciliate and human telomerase RNAs results in
impairment of the catalytic activityof the telomerase complex,
highlighting the importance of the formation of this secondary
structure for the enzyme’s function (18–22). To test if the
chimeric enzyme activity was dependent on the tTR pseudo-
knot sequences and potentially structures, we created substi-
tution mutations within the sequences implicated in the
formation of the tTR pseudoknot, stem IIIa and stem IIIb
(Figure 1A). Speciﬁcally, tTR stem IIIb nucleotides 84–87
were replaced by nucleotides 69–72 (htTR stem IIIb) and
tTR stem IIIa nucleotides 76–83 were replaced by nucleotides
92–99 (htTR stem IIIa) (Figure 1A).
Telomerase reconstituted with htTR stem IIIb and htTR
stem IIIa exhibited 7 and 14%, respectively, of the activity
reconstitutedwithhTR,comparedto19%forhtTR(Figure2D,
lanes 2–5). Thus, reconstitution of activity by htTR was sig-
niﬁcantly impaired by the stem IIIb substitution, indicating
that tTR pseudoknot sequences and possibly structures con-
tribute to the activity of the chimeric enzyme
The chimeric enzyme is nonprocessive in vitro
The pseudoknot/template region of hTR constitutes a domain
that regulates the processivity of human telomerase (8,21).
When hTR sequences are substituted for mTR residues in
the pseudoknot/template domain, the reconstituted telomerase
enzyme demonstrates defects in processivity (21). Similarly,
deletion and substitution mutations between hTR nucleotides
65 and 208 results in a complete loss of repeat addition pro-
cessivity (8). In the same way, the Tetrahymena telomerase
RNA pseudoknot has been implicated in processivity (24). To
characterize the repeat addition processivity of the chimeric
enzyme, we performed a direct primer extension assay.
The chimeric enzyme synthesized less DNA than the WT
enzyme onto the telomeric primer (T2AG3)3 (Figure 2F, lanes
1 and 2). Furthermore, the chimeric enzyme seemed to be
defective in repeat addition processivity, since it was unable
to synthesize more than one telomeric repeat (Figure 2F,
lane 2). The observed longer products (Figure 2F, brackets)
were non-speciﬁc, as they were also generated in control RRL
reactions (Figure 2F, lane 3) and were absent in reactions
performed using a different primer substrate (Figure 2F,
lanes 4–6).
To test the speciﬁcity and reproducibility of the results, we
used another primer, (TG)8TAG (50). This primer aligns more
distally from the 50 boundary of the RNA template than the
primer (T2AG3)3 (Figure 2E) (50). As expected, the DNA
product proﬁle of the WT enzyme shifted upwards compared
to the elongation product pattern with (T2AG3)3 (Figure 2F
compare lanes 1 and 4), indicating that 6 nt rather than 4 nt
were added to the DNA substrates before reaching the 50
template boundary (50). As with the (T2AG3)3 primer, the
chimericenzyme exhibited an extensive loss ofrepeataddition
processivity compared to the WT enzyme (Figure 2F, lanes
4 and 5). In addition, the chimeric enzyme was also defective
in nucleotide addition processivity, speciﬁcally at position
P + 2 (T in the sequence TTAGGG) where processivity
was reduced by 32% compared to the wild-type enzyme. In
the event that sequences in the tTR pseudoknot might contrib-
ute to primer interaction or primer utilization, we tested the
(T2G4)3 primer (Figure 2G). Though both WT and chimeric
enzymes were able to elongate the (T2G4)3 primer, the
chimericenzyme exhibited an extensive loss ofrepeataddition
processivity compared to the WT enzyme, as with the other
previouslytested primers (Figure2G,lanes 1and2).Therefore
we concluded that the RRL-reconstituted chimeric enzyme
exhibited defects in repeat addition processivity and levels
of DNA synthesis.
Telomerase reconstituted with htTR stem IIIa or IIIb and
assayed by the direct method generated activity levels similar
to those of telomerase reconstituted with htTR (Figure 2H).
Varying levels of long, undetectable elongation products gen-
erated by htTR-, htTR stem IIIa- and htTR stem IIIb-
reconstituted enzymes may be detectable by the more sensitive
PCR-based TRAP assay. Indeed, previous studies similarly
reported that enzymes with major defects in repeat addition
processivity can generate TRAP-detectable products (7).
The chimeric RNA interacts with hTERT in vitro
The pseudoknot/template and CR4–CR5 domains are the two
hTR regions required for hTERT binding (47,49). Since the
human pseudoknot nucleotides 57–159 are absent from the
chimera (Figure 1B), we tested the chimeric RNA for its
ability to bind hTERT. We used non-radiolabeled competitor
RNAs (hTR, positive control, and htTR) in the presence of
35S-labeledhTERT and
32P-labeledhTRreconstitutedinRRL,
in a co-immunoprecipitation assay with an anti-hTERT anti-
body. The binding of hTR to hTERT in the absence of non-
radiolabeled competitorRNA was setasthe maximum binding
[100%, Figure 3A (lane 2) and B]. Increasing concentrations
of non-radiolabeled hTR efﬁciently inhibited the interaction of
32P-labeled hTR with hTERT (Figure 3A, lanes 3–5), reducing
its binding to 26, 10 and 4%, respectively (Figure 3B). Visu-
ally, the non-radiolabeled chimeric RNA did not seem to
inhibit the formation of the
35S-labeled hTERT/
32P-labeled
hTR complex as efﬁciently as non-radiolabeled hTR
(Figure3A, lanes 6–8), especially atthe lowest concentrations,
reducing the binding only to 51 and 15% (Figure 3B). Nev-
ertheless, quantiﬁcation of four independent experiments
demonstrated that the differences observed in individual
experiments were not statistically signiﬁcant (P > 0.05)
(Figure 3B). We did not observe any signiﬁcant defects in
the binding of htTR to the hTERT RNA interaction domain
Nucleic Acids Research, 2005, Vol. 33, No. 17 54512 (RID2), a high-afﬁnity binding site reported previously to
bind preferentially to the P6.1 helix of the hTR CR4–CR5
domain (6,51) (Figures 1, 3C and D). These results suggest
that the CR4–CR5 domain structures are sufﬁciently main-
tained in htTR to allow association with hTERT. We con-
cluded that the presence of the tTR nucleotides 52–102 and
the absenceofhTRnucleotides 57–159 inhtTRdidnotabolish
the binding of the chimeric RNA to hTERT.
The chimeric telomerase RNA dimerizes
The hTR P3 helix (CR2–CR3) is a determinant of hTR dimer-
ization (Figure 1) (32). Since the chimera is missing the CR2
region required to form the P3 helix, we investigated the
capacity of the chimera to dimerize in vitro. Despite the
lack of the CR2 region (32), the chimera reproducibly dimer-
ized as efﬁciently as hTR in vitro (Figure 4A and B).
We subsequently hypothesized that other regions of the
chimera might mediate its dimerization. Though tTR does
not dimerize (33) (data not shown), we ﬁrst asked if the
Figure 3. The chimera interacts with hTERT in vitro.( A)
35S-labeled hTERT
was synthesized in RRL in the presence of equal amounts of
32P-labeled hTR
andincreasingamountsofunlabeledcompetitorRNAs,hTRorhtTR(3,30and
300 ng). The formed ribonucleoprotein complexes were immunoprecipitated
with an anti-hTERT antibody and visualized by SDS–PAGE. No competition
(NC) (B) Quantification of the association between hTR and hTERT in the
presence of competitor RNAs, expressed relative to the NC control. At least
threeindependentexperimentswereperformed.(C).Thechimerainteractswith
hTERT RID2. The same method as in (A) was used. (D) Quantification of the
association between hTR and hTERT RID2 in the presence of competitor
RNAs.
Figure 4. (AandB) The chimeradimerizes andalterationsofthe stem IIIaand
stem IIIb in the Tetrahymena pseudoknot structure do not inhibit its
dimerization. Representative results of dimerization for htTR mutants are
shown. M and D correspond to monomer and dimer positions, respectively.
(B)QuantificationofthedimerizationresultsforthehtTRmutants.Aminimum
of three independent experiments was performed for each RNA. (C and D)
Mutation in the J7b/8a region of the chimera affected its dimerization. (C)
Representative results of dimerization for htTR and hTR mutants are shown.
(D) Quantification of the dimerization values for the hTR and htTR mutants.
AveragedimerizationvaluesdidsignificantlydifferfromhTR(oneasterisk)or
the chimera (two asterisks) in a Student’s t-test.
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in the context of the hTR backbone. We tested htTR stem IIIa
and stem IIIb (Figures 1A and 2D) in dimerization assays. The
chimeric RNAs carrying mutations in stem IIIa or stem IIIb
dimerized as efﬁciently as hTR and htTR (Figure 4A and
quantiﬁcation in B). Thus, stem IIIa and stem IIIb sequences
in the chimera do not appear to regulate dimerization and other
regions of the hTR backbone might be responsible for its
dimerization.
We recently demonstrated dimerization defects for a P1
helix hTR mutant, hTR 190, containing substitution of nuc-
leotides 190–199 (8). Also, a single molecule ﬂuorescence
coincidence method, which allows the direct observation of
hTR multimerization in solution, demonstrated that the J7b/8a
single-stranded region forms a kissing loop between two hTR
molecules (52). Nevertheless, because hTR 190 contains an
additional small deletion of nucleotides 200 and 201 (8) and
because the implication of the J7b/8a region in hTR dimer-
ization has not been tested with the same method used to
demonstrate the importance of the P3 helix, we engineered
independent substitution mutations in the P1 helix and J7b/8a
regions of hTR and htTR. The mutants hTR P1sub and htTR
P1sub were generated by substituting hTR nucleotides 190–
199 with nucleotides 27–36 and the hTR 395–398 and htTR
395–398 mutants by replacing hTR nucleotides 395–398 by a
stretch of four thymidines.
Both mutations in the P1 helix (hTR P1sub) as well as in the
J7b/8a region (hTR 395–398) affected hTR dimerization
(Figure4C),leadingtoatleasta1.75-foldsigniﬁcantreduction
in dimerization compared to hTR (Figure 4D), suggesting that
the P3 helix may not constitute the only determinant of hTR
dimerization and that the P1 and the J7b/8a regions are also
implicated. The situation was different for the chimera, where
the P1 helix mutation seemed to affect its dimerization only
partially (Figure 4C). Statistical analysis of more than three
independent experiments revealed that the differences in
dimerization observed between hTR, htTR and htTR P1sub
were not signiﬁcant (Figure 4D). Only the mutation in the J7b/
8a region of the chimera signiﬁcantly altered its dimerization
(Figure 4C), reducing it by 3.5-fold compared to htTR
(Figure 4D). We concluded that in the context of the chimera,
the J7b/8a region of the hTR backbone appears to be the main
regulator of dimerization.
The chimeric enzyme is defective in telomere elongation
The integrity of the pseudoknot domain inﬂuences the
capacity of both the Tetrahymena and vertebrate enzymes
to function in vivo (19,20,36). To investigate the effect of
the chimeric RNA on the telomerase activity and assembly
of the enzyme in vivo, we introduced hTR and htTR in an
hTR-negative ALT cell line stably transfected with hTERT
(VA13-hTERT) (45). ALT cells are typically characterized
by extremely long (up to 50 kb) and heterogeneous telomeres,
including chromosome ends without telomeric signal
(46,53). First, we assessed the ability of the chimeric enzyme
to function in vivo by measuring telomerase activity of
whole-cell extracts by TRAP assay. hTR-transfected but
not vector-transfected clones reconstituted telomerase activity
(Figure 5A, lanes 3, 4 and 7). Contrary to RRL-reconstituted
chimeric enzyme, the VA13-hTERT clones transfected with
thechimeradidnotreconstitutetelomeraseactivity(Figure5A,
lanes 5 and 6). The absence of telomerase activity could not be
explained by a lack of expression of the chimeric RNA and/or
hTERT in the htTR-transfected clones (Figure 5B, lanes 3 and
4 and C, lanes 1 and 2). We also performed experiments
suggesting the unlikelihood that an insufﬁcient concentration
of cell extract or an inhibition of the PCR step in the TRAP
assay was responsible for the lack of telomerase activity of the
htTR-expressing clones (data not shown).
We then examined the effect of the reconstituted enzymes
on telomere length at the single cell level by Q-FISH analysis.
Telomerase reconstituted in the telomerase-negative VA13
ALT cell line by the expression of hTR and hTERT elongates
the shortest telomeres, which results in a marked decrease in
the number of chromosome ends without signal (i.e. naked
extremities) (45,46,54,55). Indeed, in the hTR-expressing
clones, the percentage of naked extremities was signiﬁcantly
reduced compared to the vector clone (Figure 5D). However,
in the htTR-expressing clones, no signiﬁcant differences in the
percentage of naked extremities compared to the vector clone
were detected (Figure 5D), suggesting that the reconstituted
chimeric enzyme does not function to elongate the shortest
telomeres. Hence, based on the absence of telomerase activity
in whole-cell extracts from htTR-expressing clones, and the
inability of the htTR-expressing clones to elongate the shortest
telomeres, it appears that the chimeric enzyme’s in vivo func-
tions are defective.
The chimeric RNA interacts with hTERT in vivo
As the chimeric enzyme is functionally impaired in vivo,w e
asked if the defects could be due to an absence of htTR–
hTERT interaction. To test this hypothesis, we immunopuri-
ﬁed the reconstituted wild-type and chimeric complexes with
an antibody directed against hTERT. We then analyzed the
immunopuriﬁed complexes for their activity, the expression of
the hTERT protein and the presence of the different RNAs by
TRAP assay, western and northern analyses, respectively. The
western and northern analyses revealed that the chimeric RNA
or hTR were present in the immunopuriﬁed complex together
with the hTERT protein (Figure 5F). However, the telomerase
activity levels detected for the immunopuriﬁed complexes
paralleled the telomerase activity levels reported for the
crude whole-cell extracts: the chimeric complex did not recon-
stitute telomerase activity whereas the wild-type complex did
(compare Figure 5A with E). We concluded that the loss of in
vivo activity does not seem to be due to a lack of htTR–hTERT
interaction.
DISCUSSION
Based on our hypothesis that the human and Tetrahymena
pseudoknot might be functionally interchangeable, we con-
structed an hTR-tTR chimera, called htTR, which contains
the tTR pseudoknot (nucleotides 52–102) ﬂanked by hTR
nucleotides 1–56 and 160–451. htTR reconstituted a weakly
active, nonprocessive chimeric human telomerase enzyme in
vitro, defective in telomere elongation in vivo. Functional
impairment could not be attributed to a complete loss of
htTR–hTERT interaction, in vitro or in vivo, or to defects
in dimerization in vitro.
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active nonprocessive human telomerase
enzyme in vitro
Our results indicate that the inserted tTR pseudoknot
sequences may play a role in mediating the activity of the
chimeric enzyme. First, htTR reconstituted 19% of the activity
(measured by TRAP) reconstituted by hTR. Second, mixing
hTR 1–56 and hTR 160–451 in trans upon hTERT expression
did not reconstitute telomerase activity. Importantly, disrupt-
ing tTR pseudoknot sequences and potentially structures sig-
niﬁcantly impaired the reconstitution of an active chimeric
enzyme.
Furthermore, we showed using the non PCR-based, direct
primer extension assay that htTR reconstituted a nonpro-
cessive enzyme that is defective in DNA and multiple repeat
syntheses. Low undetectable levels (by the primer extension
assay) of longer elongation products could be sufﬁcient for
detection by the more sensitive PCR-based TRAP assay.
Indeed, previous studies similarly reported that enzymes
with major defects in repeat addition processivity can generate
TRAP-detectable products (7).
Both Tetrahymena and human pseudoknot domains are cru-
cial for repeat addition processivity (8,24). Our results suggest
that in the context of the hTR backbone, tTR pseudoknot
sequences cannot mediate repeat addition processivity. In
addition, disruption of the P3 helix in htTR may contribute
to the impaired repeat addition of the chimeric enzyme. The
Tetrahymena tTR helix IV cooperates with the pseudoknot’s
stem III to regulate repeat addition processivity, and to stimu-
late processivity in trans (24,29). Furthermore, tTR stem IV
has been proposed as the functional analog of the humanCR4–
CR5, or the P6.1 helix (29). Thus, in the chimera, if the P6.1
helix stimulated and/or cooperated with the tTR pseudoknot
sequences, this event was insufﬁcient for the chimera to recon-
stitute repeat addition processivity. Additionally, though the
tTR helix IV may possess some functional similarities to hTR
CR4/CR5, unlike CR4/CR5, helix IV is not involved in high-
afﬁnity interactions with TERT. The interaction between hTR
P6.1 helix and hTERT is essential for DNA synthesis (8).
Since the chimeric enzyme synthesized reduced levels of
DNA compared to the wild-type enzyme, the P6.1 helix–
hTERT interaction may not be sufﬁcient for DNA synthesis.
Alternatively, the long-range interaction between the
P6.1 helix and the template (56) could be impaired in the
chimera due to the presence of tTR pseudoknot sequences.
The Tetrahymena and human pseudoknot domains adopt
alternate structures (14,16,57–59). Recently, two studies
Figure5. Thechimeraisdefectiveintelomereelongation.(A)TelomeraseactivityoftheVA13-hTERTclones.Atotalof1mgofwhole-cellextractswasassayedfor
telomerase activity by TRAP. As a positive control, 1 mg of whole-cell extract from telomerase-positive HL60 was tested for telomerase activity by TRAP, IC,
internalPCRcontrol.(B)hTRandhtTRexpressionintheVA13-hTERTclones.cDNAfromVA13-hTERTclonestransfectedwithpcDNA3-hTR,pcDNA3-htTRor
pcDNA3wereanalyzedbyPCRfortheexpressionofhTRorhtTR.TheplasmidsphTR + 1andphtTRwereusedaspositivecontrolsforthePCRandGADPHasan
IC for the integrity of the cDNAs. (C) hTERT expression in the VA13-hTERT clones. cDNA from VA13-hTERT clones transfected with hTR, htTR or the vector
wereanalyzedfortheexpressionofhTERTbyPCR.(D)QuantificationofthenakedextremitiesinVA13-hTERTclonesbyQ-FISH.Aminimumof15metaphases
were prepared for each clone (as indicated by the number on the bar of the graph). n.s., non statistically significant; m, number of metaphases prepared. The results
were expressed as a ratio of naked extremities over the total extremities measured by Q-FISH in one vector clone, two clones expressing hTR and in three clones
expressing htTR.Average valueswere analyzed by a Student’s t-test, and P-values from comparisonbetween different clones are indicated. (E and F) The chimera
assembles with hTERT in vivo but is not active by TRAP. Telomerase was immunoprecipitated from whole-cell extracts made from hTR-transfected, htTR-
transfectedorvector-transfectedclonesandthetelomerase-positivehumancellline,HL60,usingananti-hTERTantibody(E)10%oftheresultingbeadswereusedto
perform a TRAP assay on the immunopurified complex.Thirty percent of the beads were used to reveal the presence of the hTERTprotein by western blot analysis
with the same antibody used for the immunopurification (F, top panel). Sixty percent of the beads were used to reveal the presence of hTR and htTR in the
immunopurified complex by northern blot with a probe directed against a common region of the two RNAs (F, bottom panel).
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ture (59,60). Stable triple helix formation strongly correlates
with telomerase activity (59). It is possible that the triple helix
does not form in the chimeric RNA, and may explain its
defects. The proper folding of the Tetrahymena pseudoknot
has also been reported to be TERT-dependent in vitro and in
vivo (19,61). It has been proposed that the conformational
transition of the pseudoknot may help to dissociate the
RNA–DNA duplex before the translocation of the enzyme
to generate another repeat (24,26). Thus, it is possible that
the tTR pseudoknot in the chimera is unable to perform this
transition, perhaps because it cannot interact with regions
speciﬁc to hTERT, therefore rendering the enzyme nonpro-
cessive.
The chimera binds hTERT
Mutations scattered throughout the pseudoknot/template
domain, including in the P1 helix and near the template,
do not detectably affect the binding of hTR to hTERT (22).
Similarly, the chimera was able to interact with hTERT.
The binding of hTR tothe N-terminalhTERTRNA interaction
domain 1 (RID1) has been mapped to the pseudoknot/template
domain (hTR 1–209) (7,8). As RID1 is a weak afﬁnity hTR
binding site, defective interactions that might be predicted
between hTERT RID1 and the altered pseudoknot/template
domain in the chimeric RNA might be difﬁcult to detect in
the context of full-length hTERT and RNA, in which the
high-afﬁnity hTERT–hTR interactions mediated by RID2
and hTR CR4–CR5 are presumably intact. Alternatively,
the introduced Tetrahymena sequences might be contributing
to hTERT binding, or the hTR sequences important for
binding to RID1 may map to nucleotides within 1–56 or
160–209, that are not changed in the chimera and that
have not been previously altered in published studies
(16,22). A TLC1–hTR chimera, called tlc1-96, in which the
S.cerevisiae pseudoknot was replaced by hTR pseudoknot
nucleotides 90–183, has recently been shown to demonstrate
a 50-fold reduction in its binding to the catalytic subunit Est2p
compared to TLC1 (35). These results and our data suggest
that pseudoknot sequences or structures may be less critical
for hTR interactions with hTERT than TLC1 association
with Est2p.
The chimera dimerizes
The P3 helix of the human pseudoknot/template domain was
ﬁrst implicated in the dimerization of the human telomerase
RNA (32). More recently, the involvement of the P1 helix
and the J7b/8a loop in dimerization has been reported
(8,52). Mutations in either region reduced hTR dimerization
tolevelsreportedforhTR P3helixmutants,suggestingthatthe
P1 helix and J7b/8a are as important as the P3 helix in regu-
lating hTR dimerization. In the absence of the P3 helix in the
chimera, the J7b/8a region, but not the P1 helix appeared to be
important for htTR dimerization, suggesting that the P3and P1
helices may not play a crucial role in htTR dimerization. We
speculate that the presence of the tTR pseudoknot sequences
may alter the normal folding of the pseudoknot/template
region and impair the formation of hTR dimers via the P3
and P1 helices.
The role of hTR dimerization in telomerase function is still
unclear. Our results with the chimera support the previously
reported evidence that hTR dimerization is not sufﬁcient for
repeat addition processivity (8). One could also envision that
the dimerization mediated by different hTR regions is not
functionally equivalent. For instance, dimerization via the
P3 helix, which is absent in the chimera could be the most
critical for repeat addition processivity. Interestingly, the P1
helix, though it mediates dimerization, is not essential for
repeat addition processivity (8). Clearly, more studies are
needed in order to clarify the role of hTR dimerization in
human telomerase function.
The chimeric enzyme is defective in telomere elongation
Mutations in the pseudoknot/template domains of yeast and
human telomerase RNAs can impair the ability of telomerase
to properly maintain telomere length. (35–37,39). Yeast
expressing telomerase reconstituted with a TLC1–hTR
chimeric RNA (tlc1-96) containing human pseudoknot
sequences are also defective in the maintenance of wild-
type telomere length (35). However, yeast expressing a
TLC1–Oxytricha nova chimeric RNA maintain almost wild-
type length telomeres (35).
As varying levels of mouse telomerase activity can be
reconstituted by the in vivo assembly of mouse telomerase
with pseudoknot mutant mTRs (20), and because the chimeric
enzyme was partially active in vitro, we considered that
the chimeric enzyme might be partially functional at
the telomeres. Instead, no telomerase activity was detectable
from whole-cell extract made from telomerase-negative cells
expressing hTERT and htTR, and the chimeric enzyme was
defective in telomere elongation. At the present time, we can-
not dismiss the possibility that the chimeric enzyme is not
recruited to the telomeres. However, the lack of activity is
not due to an inability of the two components to interact since
the chimera could be co-immunoprecipitated with hTERT
from the whole-cell extracts. Though htTR and hTERT can
interact in the cell extracts, the functional assembly of the
chimeric enzyme in a cell could differ from the functional
assembly in the cell-free RRL system. It is also likely
that the chimeric enzyme’s defects in repeat addition pro-
cessivity and in DNA synthesis might be sufﬁcient to prevent
proper function at the telomeres. The defect of the chimera,
which contains a large alteration of its pseudoknot region, to
elongate the shortest telomeres was more pronounced that the
defect in telomere elongation recently reported for a mutant
hTR (hTR-DC) carrying the GC to AG double substitution in
the pseudoknot nucleotides 107–108 (62). Interestingly,
telomerase reconstituted with hTR-DC, which is mutated
in autosomal DC, is defective in DNA synthesis in vitro,
but exhibits almost wild-type levels of repeat addition
processivity (8).
Though telomerases from ciliates, yeasts and vertebrates
share common features, some distinct characteristics include,
but are not limited to, differences in enzyme repeat addition
processivity and telomere length. The exchange of sequences
and structures between telomerases from different species
such as reported here and previously (21,27,35) will continue
to provide insights regarding the distinct mechanisms that
mediate species-speciﬁc differences in enzyme function.
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